Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials

Eur J Cancer. 2016 Nov:67:119-129. doi: 10.1016/j.ejca.2016.08.006. Epub 2016 Sep 16.

Abstract

Purpose: To assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with International Union Against Cancer (UICC)-staged III/IVA,B nasopharyngeal carcinoma (NPC), who were enrolled into two randomised controlled trials of concurrent/adjuvant chemotherapy when added to radiotherapy (SQNP01), and induction chemotherapy when added to chemoradiotherapy (NCC0901).

Material and methods: A post hoc analysis of pooled cohorts from SQNP01 (N = 221) and NCC0901 (N = 172) was performed. We employed a threshold of pre-treatment NLR = 3.0 (median) to stratify patients. Survival outcomes were compared using log-rank test. Multivariable Cox regression analyses were performed to assess association between NLR and overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS).

Results: High NLR (≥3.0) was associated with advanced T-status (p = 0.002), N-status (p = 0.002), overall UICC stage (p = 0.004), and high pre-treatment Epstein-Barr virus DNA titre (p = 0.001). High NLR was not associated with OS (0.94 [0.67-1.32], p = 0.7), DFS (0.98 [0.73-1.33], p = 0.9), DMFS (1.02 [0.66-1.57], p = 0.9), and LRFS (1.37 [0.84-2.22], p = 0.2) on univariable and multivariable analyses, while conventional clinical indices (T-status, N-status, and overall UICC stage) were prognostic of clinical outcomes. High NLR also did not predict for a treatment effect with the experimental arms in both trials.

Conclusion: Our pooled analyses that were confined to a homogenous patient population of locally advanced NPC do not suggest that NLR adds prognostic value to conventional clinical indices in identifying patients with unfavourable disease.

Keywords: Biomarker; Locally advanced; Nasopharyngeal carcinoma; Neutrophil-to-lymphocyte ratio; Prognosis.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carcinoma / blood*
  • Carcinoma / pathology
  • Carcinoma / therapy
  • Carcinoma / virology
  • Cisplatin / administration & dosage
  • DNA, Viral / blood
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • Epstein-Barr Virus Infections / blood
  • Female
  • Fluorouracil / administration & dosage
  • Gemcitabine
  • Herpesvirus 4, Human / genetics
  • Humans
  • Leukocyte Count
  • Lymphocyte Count
  • Lymphocytes*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms / blood*
  • Nasopharyngeal Neoplasms / pathology
  • Nasopharyngeal Neoplasms / therapy
  • Nasopharyngeal Neoplasms / virology
  • Neoplasm Staging
  • Neutrophils*
  • Prognosis
  • Proportional Hazards Models
  • Radiotherapy
  • Randomized Controlled Trials as Topic
  • Singapore
  • Survival Rate

Substances

  • DNA, Viral
  • Deoxycytidine
  • Carboplatin
  • Cisplatin
  • Fluorouracil
  • Gemcitabine